BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

Table 1 Gene mutation profiles of the colon cancer cell lines used in this study

Cell Line	RAS	BRAF	PI3KCA	EGFR	TP53	APC	SMAD4	other
SW-48	wt	wt	wt	c.2155G > A p.G719S	wt	wt	wt	CTNNB1 c.98C > A p.S33Y
SW-48	wt	wt	wt	c.2155G > A p.G719S	wt	wt	wt	FBXW7 c.2001delG p.S668 fs*39
Colo205	wt	c.1799 T > A	wt	wt	c.308_333 > TA	c.4666_4667insA	c.1_667del667	–
Colo205	wt	p.V600E	wt	wt	p.Y103_L111 > L	p.T1556 fs*3	c.1_667del667	–
HT-29	wt	c.1799 T > A p.V600E	c.1345C > A p.P449T	wt	c.818G > A R273H	c.2557G > T p.E853* c.4666_4667insA p.T1556 fs*3	c.931C > T p.Q311*	–

ISSN: 1471-2407